associ genom prostat score multiparametr prostat mri low intermedi risk prostat pca michael antonneio niloufar jeffrey phillip matthew depart urolog connecticut unit state urolog california san francisco san francisco california unit state radiolog california san francisco san francisco california unit state genom inc redwood citi california unit state epidemiolog biostatist california san francisco san francisco california unit state current address urolog connecticut unit state michael leapman edu background aim direct result multiparametr prostat mri mpmri biopsybas rtpcr assay provid genom prostat score gps individu candid activ surveil low intermedi risk pros tate pca patient method evalu associ gps result scale endorect mpmri find clinic localis pca review fiveti scale increas suspicion malign appar diffus coeffici adc calcu late singl domin lesion rank gps mri strata compar kruskalw test dunn multipl test spearman correl perform examin associ adc scale gps result patient gps test identifi mpmri gps result differ mpmri categori broad rang mpmri categori biopsi gleason pattern gps result signific differ mri group gps differ enc mri categori patient pattern adc weak associ gps stromal open citat leapman westphalen ame lawrenc febbo cooperberg associ genom prostat score multiparametr prostat mri low intermedi risk prostat pca plos https pone aamir ahm king london unit kingdom publish copyright open free copyright freeli reproduc distribut transmit modifi built otherwis use anyon law purpos made creativ common domain dedic data avail statement deidentifi data ucsf institut data ethic committe research meet confidenti data inform pleas contact niloufar ame ucsf edu fund author jeffrey lawrenc hjl phillip febbo fulltim employe genom inc redwood citi hjl review prior plos https pone submiss genom inc play role design data collect decis publish provid financi support form author salari specif role author articul contribut section compet interest author read polici author compet interest hjl pgf employ genom inc mrc prc department support genom inc alter adher plos polici share data materi associ mri genom profil prostat organis group score differ signific mri find differ androgen signal prolifer gene conclus statist signific associ gps result mri score wide rang gps valu imag categori suggest mpmri genom profil offer overlap insight introduct major diagnos prostat pca low intermediaterisk diseas present basi patholog factor yet perform best predict instrument mischaracteris propor tion harbour occult higher grade stage diseas abil offer improv risk stratif import effort shape trajectori initi manag decis choic increas defin activ surveil immedi tissuebas express assay multiparametr prostat magnet reson imag mpmri consider attent potenti add predict valu beyond convent model determin presenc high grade nonorgan confin diseas gain utiliza tion earli diseas manag biopsi base assay reflect quantit express gene associ tumour aggress demonstr predict valu advers patholog radic prostatec tomi well downstream oncolog endpoint includ biochem recurr bcr metastat progress valid tool predict perform exceed convent patholog variabl similar high resolut mri examin multipl imag parametr offer anatom biolog ical insight tumour stage grade offer higher degre accuraci stage tumour local likelihood advers downstream event unclear modal offer congruent independ biolog inform date publish exist direct test subject specif unknown advers find mri deriv benefit tissuebas assay convers mri add meaning inform alreadi tissu base test context sought evalu associ mpmri find gps clinic favour pca initi diagnosi hypothesis strong correla tion exist mri find gps result patient method patient select california san francisco ucsf institut board approv retrospect identifi consent patient low intermediaterisk pca underw endorect coil mpmri biopsybas rtpcr assay oncotyp prostat assay provid genom prostat score gps measur tumour aggr sive within maxeimum year patient record deidentifi plos https pone associ mri genom profil prostat analys anonym patient initi biopsi institut diagnost biopsi perform use extend sextant systemat sampl techniqu includ minimum core perform refer centr review genitourinari pathologist gleason score diseas diseas risk defin use valid prostat risk assess score ucsfcapra mpmri test obtain discret provid local stage tool earli stage diseas consid enrol diseas stabil sequenc includ high bvalu diffusionweight imag dwi spectro scopic imag mrsi dynam contrast enhanc dce scan acquir scanner healthcar waukesha use bodi coil excit endorect coil ecoil medrad pittsburgh fill perfluorocarbon phase array coil recept imag postprocess compens recept profil endorect coil mri rereview genitourinari radiologist year experi blind biopsi gps result grade scale increa ing suspicion malign modif pirad system appar diffus coeffici adc calcul singl domin lesion combin imag genom profil routin recommend multiparametr prostat mri score rubric peripher zone homogen high streaki triangular geograph area low discret nodul low evid ece capsular contact transit zone heterogen organis chao foci low well margin encapsul foci homogen low defin evid ece capsular contact diffus weight imag dwi high valu dwi iso high iso high high adc iso iso low low low adc valu magnet reson spectroscopi imag mrsi citrat peak cholin peak citrat peak cholin peak citrat peak cholin peak cholin peak citrat peak cholin peak citrat peak dynam contrast enhanc dce asymmetr earli enhanc quick washout plateau pattern enhanc https pone plos https pone associ mri genom profil prostat low intermedi risk diseas prior enrol refin risk assess oncotypedx prostat assay genom inc redwood citi perform use rna extract fix paraffinembed diagnost prostat needl biopsi biopsybas rtpcr assay generat genom prostat score gps scale biolog measur tumour aggress valid independ predictor favour surgic patholog surgic organconfin diseas gps repres weight calcul express signatur includ gene high associ prostat recurr metastas refer gene control rna qualiti quantiti constitu group repres gps includ androgen signal stromal bgn organis flnc gsn prolifer statist primari object evalu associ mpmri find gps result observ cohort clinic localis prostat compar rank scale gps mri result characteris nega score indetermin suspici use kruskalw test examin differ group perform post hoc pairwis use dunn multipl test method retain depend rank produc kruskalw test statist incorpor pool varianc estim pre serv familywis error rate use adjust signific level defin number comparison examin particular associ individ ual group find repeat kruskalw analys within express baselin characterist patient receiv multiparametr prostat mri gps test patient characterist age year median iqr psa median iqr prostat median iqr psa densiti median iqr race ethnic tstage core median iqr core median iqr core median iqr singl core median iqr capra valu asian pacif island low intermedi high statist abbrevi iqr interquartil rang psa prostatespecif antigen capra prostat risk assess miss data total sum patient https pone plos https pone associ mri genom profil prostat score group diffus weight imag dwi propos quantita measur associ tumour aggress sought examin associ appar diffus coeffici adc gps use spearman correl perform pool patient well stratifi capra risk categori biopsi statist analys perform use sas softwar sas institut cari north carolina result consent undergon gps test institut identifi mpmri within window genom test compar undergo ing combin mri gps test undergo gps test alon similar match baselin demograph diseas characterist patient receiv mri gps median age year median psa iqr biopsi includ median core interquartil rang iqr median core iqr biopsi major patient sought initi manag ulti mate underw radic prostatectomi patholog featur present mri find patient indetermin median gps iqr iqr indetermin iqr mri signific differ rank gps result mri categori entyr group patient gps increas increas mri categori nonetheless wide distribut gps valu within mri categori patient stratifi biopsi signific associ gps mri patient signific associ tumour posthoc pairwis comparison show signific differ enc rank gps mri categori statist signific differ indetermin pos itiv indetermin result high suspicion mri lesion evalu associ scale gps result meanadc valu weak trend toward higher gps result lower meanadc valu rho determin associ exist within individu pathway sure gps mri find examin associ group express level mri find stromal organis express score show modest statist signific associ mri categori respect signific trend androgen prolifera tion respect meanadc exhibit weak associ vidual group stromal rho organis rho androgen signal rho prolifer rho within pathway consider variat express level mri group particular patient categori lesion limit convent variabl reliabl characteris extent diseas newli diagnos pca grow arsenal tool aim risk estim earli stage diseas genom signatur valid pre dict occurr higher grade stage element clinic favour risk patient plos https pone associ mri genom profil prostat distribut gps score mri find patient https pone high resolut mpmri anatom biolog inform modal extens abil detect signific compar anal yses advanc risk stratif tool lack remain unclear distribut gps result mri find biopsi gleason grade patient gleason grade https pone plos https pone associ mri genom profil prostat meanadc valu domin mri lesion gps result https pone individu imag deriv benefit genom test convers imag benefit tissuebas assay examin associ mri find gps signatur cohort clinic favour risk pca undergo evalu modal iti trend toward higher gps result exist higher mrsuspicion lesion consider variat mpmri find suggest biolog heterog neiti within mri categori without mrevid tumour gps result tend lower narrowli distribut repres minor patient indetermin gps result rang signific persist stratif risk group though direct correl patient find refin patient beyond mri find alon gps assay deriv set high predict gene fashion independ gleason pattern valid independ predictor patholog upgrad upstag favour risk diseas distant oncolog outcom includ biochem recurr meta static progress specul imag find recapitul tumour express level higher suspicion mri lesion associ higher gps score higher express level stromal prolifer gene associ mrevid diseas area restrict diffus associ higher gps find gps result signific differ patient plos https pone associ mri genom profil prostat distribut individu group express level mpmri categori https pone indetermin mri scan biopsi pattern though signific differ mri group biopsi pattern moreov stromal organis express score associ ate find though associ androgen signal prolif erat group prior valid demonstr signific associ primari group includ recurr find indic radiom basi stromal organis gene pattern find degre agreement signal direc tion exist mri gps assay inform provid modal larg nonoverlap prognost signific visibl lesion mpmri evalu sever pca endpoint includ detect higher grade gleason diseas biopsi progress high grade stage patholog prostatectomi biochem recurr newli diagnos pca presenc mridiscern lesion suggest advers prognost particular initi agement retrospect suggest increas risk diseas plos https pone associ mri genom profil prostat reclassif chang tumour estim mri incorpor multipl sequenc believ reflect anatom tumour vascular cellular higher rate upgrad reflect improv sampl associ larger tumour occurr genuin biolog progress though mri exhibit capac identifi higher gleason pattern pca genet mechan under mri find remain fulli elucid adc valu exhibit weak correl gps constitu group find notabl prior address associ appar diffus coeffici adc prostat aggress direct consist implic restrict diffus tumour aggress strength associ impli meanadc close parallel panel gene high associ pca aggress includ biopsi sampl obtain use systemat extend sextant sampl direct mrultrasound fusion acquisit reflect collect institut result abl express profil perles basi addit grow appreci improv diagnost yield associ mrultra sound fusion conceiv degre undersampl relat target method gps assay previous prostat cer aggress biopsi undersampl heterogen gleason grade hold valid assess broader tumour profil gland though fur ther warrant use imageguid wholemount correl import insight appear offer intriguig preliminari direct radiom match express express featur mpmridirect diagnost biopsi associ radiograph abnor maliti aberr express highlight measur basi charac terist find acknowledg limit restrict modal without direct evalu outcom find reflect favour risk cohort routin use initi manag appropri candid result small proport immedi definit prostatectomi limit abil offer patholog addit patient receiv genom test without mri even match conclud certainti decis pursu mri gps test patient occur random individu opt multipl modali tie advanc test prefer patient possess unrecog nize complex warrant addit evalu addit imag review singl radiologist limit reproduc utilis twoyear interv mri gps test inclus assumpt diseas stabil base model observ chang tumour occur period last design examin gps result biopsi select mri abnormali tite grow utilis mriultrasound fusion platform afford direct sampl mrappar lesion limit prevent compar genom profil base direct biopsi tissu base genom profil mri seek offer refin stage risk stratif diagnosi includ risk advers patholog geri host public support use mri stage presenc extraprostat extens semin vesicl invas similar gps assay clinic valid patholog outcom includ patient plos https pone associ mri genom profil prostat receiv radic prostatectomi patient imag genom profil context establish elig minor underw prostatectomi last resut direct comparison limit sampl size select bias patient receiv context biopsi upgrad concern progress optim detect signific differ expr sion strata mri find correspond pirad classif esti mate patient requir appropri power requir relat util imag genom profil initi risk stratif direct compar associ generat pca risk predict tool recent renardpenna examin patient treat preoper mpmri find compar genom test tumour tissu progress assay measur aggress note associ tumour size diffus abnorm advers cellcycl progress ccp score interest author utilis ccp benchmark assess perfor manc preoper imag valuabl opportun remain modal particular pretreat set inventori risk refin aid expand size complex like direct comparison increa ing potenti serv effici direct resourc find mpmri gps assay offer predict inform dis tinctiv mani circumst reflect intrins differ tool prostat score system includ pirad framework develop calibr detect clinic signific appris larg basi gleason score power though altogeth incomplet predictor diseas contrast gene select gps assay relat weight within generat score valid pre dict advers patholog oncolog event independ patholog assess result anticip heterogen express level exist within mri group find underscor variabl within mri group intersect multipl pca risk refin tool earli stage pca present unexplor avenu implic diseas manag find reflect commerci assay stratif mri find yet alon inadequ dictat definit sequenc test addit compara imag serum detectionori biomark prove fruit clarifi optim diagnost pathway addit larger popul assess stream pca outcom requir optim sequenc emerg modal compar mpmri tissu base express test low intermedi risk patient prostat mri genom test gps assay exhibit weak correl suggest modal repres independ predictor complementari guid patient manag contribut conceptu michael leapman matthew cooperberg carrol data curat michael leapman antonneio westphalen carrol formal niloufar ame carrol plos https pone associ mri genom profil prostat methodolog michael leapman antonneio westphalen niloufar ame jeffrey law renc matthew cooperberg project administr michael leapman carrol resourc michael leapman jeffrey lawrenc carrol softwar niloufar ame supervis antonneio westphalen carrol write origin draught michael leapman matthew cooperberg carrol write edit michael leapman phillip febbo matthew cooperberg carrol refer cooperberg broer carrol trend local variat primari local ize prostat clin oncol epub https jco pmid pubm central pmcid shariat karakiewicz suardi kattan nomogrammem method predict outcom prostat critic litreatur clin res epub https pmid thompson thrasher burnett canbyhagino cookson guidelin manag clinic localis prostat updat urolog epub https juro pmid bishoff freedland gerber tennstedt reid welbourn prognost util cycl progress score generat biopsi treat prostatectomi urol epub https juro pmid klein cooperberg magigalluzzi simko falzarano maddala assay prostat aggress context gleason grade heterogen tumour multifoc biopsi undersampl european urolog epub https eururo pmid somford hamoen futter basten hulsbergenvan kaa vreul predict valu endorect tesla multiparametr magnet reson imag extrapro static extens patient low intermedi high risk prostat urol epub https juro pmid gondo hricak sala zheng moskowitz bernstein multiparametr mri predict patholog downgrad radic prostatectomi patient biopsyproven glea score prostat eur radiol https pmid cullen rosner brand tsiati moncur biopsybas genom prostat score predict recurr radic prostatectomi advers surgic patholog racial divers popul clinic low intermediaterisk prostat euro pean urolog epub https eururo pmid salami vira turkbey fakhouri yaskiv villani multiparametr magnet reso nanc imag outperform prostat prevent trial risk calcul predict clinic signific prostat epub https cncr pmid gupta faridi singh passoni garciarey madden compar parametr mri partin tabl organconfin prostat radic prostatec tomi urol oncol https urolonc pmid cooperberg pasta elkin litwin latini chane califor nia san francisco prostat risk assess score straightforward reliabl preop erat predictor diseas recurr radic prostatectomi urol https pmid pubm central pmcid flavel westphalen liang sotto noworolski vigneron abnorm find multiparametr prostat magnet reson imag biopsi upgrad plos https pone associ mri genom profil prostat patient low risk prostat manag activ surveil abdom imag epub https pmid pubm central pmcid pickl gibb sreeniva turnbul diffusionweight imag normal malign prostat tissu magn reson imag epub https jmri pmid cullen rosner brand tsiati moncur biopsybas genom prostat score predict recurr radic prostatectomi advers surgic patholog racial divers popul clinic low intermediaterisk prostat eur urol https eururo pmid knezev goddard natraj cherbavaz clarklangon snabl analyt vali dation oncotyp prostat assay rtpcr assay optimis prostat nee dle biopsi genom epub https pmid pubm central pmcid dunn multipl comparison statist associ donati mazaheri afaq varga zheng moskowitz prostat aggr sive assess wholeles histogramm appar diffus coeffici radiol ogi epub https radiol pmid siddiqui raisbahrami turkbey georg rothwax shakir ultrasound fusionguid biopsi ultrasoundguid biopsi diagnosi prostat jama https jama pmid pokorni rooij duncan schroder parkinson barentsz prospect diagnost accuraci compar prostat detect transrect ultrasoundguid biopsi magnet reson imag mrguid biopsi without prostat biopsi eur urol https eururo pmid abdalazeez ahm arya dikaio freeman multiparametr mag netic reson imag upgrad transrect ultrasound biopsi result definit histolog urol oncol epub https urolonc pmid park park park cho prostat role pretreat multipara metric mri predict biochem recurr radic prostatectomi ajr roentgenol https ajr pmid dianat carter pienta schaeffer landi epstein magnet resonanceinvisi magnet resonancevis prostat activ surveil preliminari report diseas outcom urolog https urolog pmid filson natarajan margoli huang lieu dorey prostat detect magnet resonanceultrasound fusion biopsi role systemat target biopsi epub https cncr pmid pubm central pmcid stoyanova pollack takhar lynn parra lam associ multiparametr mri quantit imag featur prostat express mritarget prostat biopsi oncotarget epub https oncotarget pmid klotz vesprini sethukavalan jethava jain longterm followup larg activ surveil cohort patient prostat clin oncol https jco pmid inou trock partin carter etzioni model grade progress activ surveil lanc stat https sim pmid pubm central pmcid morlacco sharma vier rangel carlson froem increment role magnet reson imag prostat stage radic prostatectomi european urolog epub https eururo pmid brand crager maddala dee sesterhenn patientspecif metaanalysi valid patholog outcom prostat use genom prostat score urolog epub https urolog pmid plos https pone associ mri genom profil prostat renardpenna canceltassin comperat varinot laeon roupret multiparametr magnet reson imag strong predict postop patholog miss aggress pros tate cancer assess cycl progress score urol epub https juro pmid barentsz richenberg clement choyk verma villeir esur prostat guidelin eur radiol epub https pmid pubm central pmcid plos https pone